Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 uspstf recommendations
Menée aux Etats-Unis à partir des données d'une enquête portant sur 1 222 patients ayant consulté un urologue ou un médecin généraliste entre 2010 et 2012 (âge : 50 à 74 ans), cette étude analyse l'évolution de l'usage du test PSA avant et après la publication des recommandations 2012 de l'US Preventive Services Task Force
This survey study compares the use of prostate-specific antigen testing among men aged 50 to 74 years before and after the 2012 United States Preventive Services Task Force guidelines were issued.
The use of prostate-specific antigen (PSA) testing for early detection of prostate cancer remains controversial.1 In October 2011, the US Preventive Services Task Force (USPSTF) issued a recommendation against PSA screening for all men.2 This change was associated with a decline in rates of PSA testing among men aged 50 to 74 years and a decline in cases of incident prostate cancer.3,4 Given the evidence for heterogeneity in screening practices,5 we sought to compare the use of PSA testing among urologists vs primary care physicians (PCPs) before and after the latest USPSTF guidelines, hypothesizing that the adoption of these recommendations would vary according to physician specialty.
JAMA Internal Medicine , résumé, 2015